Adaptive Biotechnologies (ADPT) FCF Margin (2018 - 2026)

Adaptive Biotechnologies has disclosed FCF Margin across 9 years of filings, most recently posting 14.58% for Q1 2026.

• FCF Margin for Q1 2026 came in at 14.58%, up 4014.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.35% (up 3613.0% YoY), and the FY2025 annual result was 17.67%, up 3758.0% from the prior year.
• FCF Margin came in at 14.58% for Q1 2026 at Adaptive Biotechnologies, down from 0.33% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 0.33% in Q4 2025 to a low of 370.47% in Q2 2023.
• The 5-year median for FCF Margin is 57.47% (2023), against an average of 85.02%.
• Across the five-year window, FCF Margin sank 26219 bps in 2023 and surged 32548 bps in 2024, its largest moves.
• Adaptive Biotechnologies' FCF Margin stood at 52.75% in 2022, then retreated by 9 bps to 57.47% in 2023, then soared by 54 bps to 26.49% in 2024, then soared by 99 bps to 0.33% in 2025, then slumped by 4328 bps to 14.58% in 2026.
• The last three FCF Margin figures came in at 14.58% (Q1 2026), 0.33% (Q4 2025), and 8.06% (Q3 2025), per Business Quant data.